NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Anbio Biotechnology

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026

$3.27+0.14 (+4.47%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Anbio Biotechnology has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Announcements Anbio Biotechnology filed with the SEC

Parsed from the XBRL in Anbio Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NNNN.

Revenue growth5.6% · median -1.4%

Gross margin87.2% · median 37.5%

Operating margin66.7% · median -80.7%

Net margin74.1% · median -76.9%

Advertisement
300 × 250